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Bipolar disorder (BD), one of the most debilitating mental disorders, is associated with
increased morbidity and mortality. Lithium is the first line of treatment option for BD and
is often used for maintenance therapy. Recently, the neuroprotective action of lithium has
gained tremendous attention, given that BD is associated with structural and functional
abnormalities of the brain. However, the precise molecular mechanism by which lithium
exerts its neuroprotective action is not clearly understood. In hippocampal neurons, the
effects of lithium (1 and 2mM) on neuronal viability against glutamate-induced cytotoxicity,
dendritic length and number, and expression and methylation of BDNF promoter exons
and expression of apoptotic regulatory genes were studied. In rat hippocampal neurons,
lithium not only increased dendritic length and number, but also neuronal viability against
glutamate-induced cytotoxicity. While lithium increased the expression of BDNF as
well as genes associated with neuroprotection such as Bcl2 and Bcl-XL, it decreased
the expression of pro-apoptotic genes Bax, Bad, and caspases 3. Interestingly, lithium
activated transcription of specific exon IV to induce BDNF gene expression. This was
accompanied by hypomethylation of BDNF exon IV promoter. This study delineates
mechanisms by which lithium mediates its effects in protecting neurons.
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INTRODUCTION
Bipolar disorder (BD) is one of the most debilitating disorders,
which affects about 1% of the population in the world (Schroeder
et al., 2011). Among various mental disorders, BD is associated
with the highest risk of suicide (Nock et al., 2009), characterized
by often cyclothymic and irritable temperaments, which leads
to increased risk of suicide up to 20 times that of the average
population (Pompili et al., 2013).
Several clinical studies suggest that BD is associated with
changes in the brain structure and imbalance in signal trans-
duction mechanisms that can lead to altered cellular integrity
and synaptic plasticity. For example, a magnetic resonance spec-
troscopy (MRS) study demonstrates that BD is associated with
neuronal and glial stress, neuronal atrophy, and cell death (Glitz
et al., 2002). Further, bipolar patients show reduced gray matter
volume in medial prefrontal cortex, amygdala, and ventral and
orbitofrontal cortices (Brambilla et al., 2005). In addition, reduc-
tion in neuronal size and changes in neuronal density in medial
prefrontal cortex of bipolar patients have been reported (Savitz
et al., 2014). MRS studies also demonstrate that cellular signaling
pathways that are critical for neuronal protection are significantly
altered in prefrontal cortex, anterior cingulate cortex, and hip-
pocampus of bipolar patients (Yildiz-Yesiloglu and Ankerst, 2006;
Visnjic and Banfic, 2007).
Several studies suggest that brain-derived neurotrophic fac-
tor (BDNF), a protein involved in neuronal survival, dendritic
branching, and synaptic plasticity (Huang and Reichardt, 2001),
is lower in the brain and serum of bipolar patients (Cunha et al.,
2006; Monteleone et al., 2008). Lower BDNF gene expression in
bipolar patients could be associated with epigenetic modifications
(D’Addario et al., 2012; Gao et al., 2012). BDNF mediates its
neurotrophic action after binding to and activating tropomycin-
receptor kinase B (TrkB). This leads to signaling cascade of
events within neurons, mediated by extracellular signal-regulated
kinases (ERKs) and phosphoinositide 3-kinase (PI3K) (Huang
and Reichardt, 2001). Interestingly, it has been shown that not
only is the activation of TrkB less active in the brain of bipolar
patients but ablation of ERK activation can leads to hyperactivity
in rodents (Engel et al., 2009). In addition, an association between
AKT1 genetic variants and BD has been shown which increases
the suicidal risk in these patients (Karege et al., 2010;Magno et al.,
2010). One of the major functions of BDNF-mediated ERK1/2
and PI 3-K/Akt signaling is to regulate proteins involved in cell
survival. This occurs via the Bcl-2 family of proteins and the cys-
teine protease caspase family. Bcl2 family proteins are divided into
two groups: anti-apoptotic (Bcl2 and BclxL) and pro-apoptotic
(Bax and Bak, Bid, Bad, and Bim) (Lucken-Ardjomande and
Martinou, 2005). Pro-death Bcl2 family members initiate a cell
death program, which involves opening of the mitochondrial
permeability pore, decreases in the mitochondrial membrane
potential, and the release of cytochrome C. This results in the
nucleation of apoptosome, comprised of Apaf-1, cytochrome c,
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and caspase 9, which then cleaves and activates caspase-3, the
main executioner of the apoptotic cascade (Yuan and Yankner,
2000). BclxL binds to Apaf-1 and blocks the ability of Apaf-1
to activate pro-caspase 9 which is antagonized by Bax (Schulze-
Osthoff et al., 1998). The Bcl2 gene contains a CRE-binding site
and activation of CREB via ERK1/2 can lead to increased synthesis
of Bcl2 gene (Wilson et al., 1996). Expression of Bcl-xL is regu-
lated by p90RSK in response to ERK1/2 activation. A recent study
shows polymorphism in Bcl-2 gene (rs956572) in BD patients
(Soeiro-de-Souza et al., 2013). In addition, decreased density of
neurons and glia and decreased size of neurons in frontal and sub-
cortical areas of bipolar brain could be due to increased apoptosis
(Gigante et al., 2011).
Lithium is the most effective mood stabilizer and is the first
line of treatment for BD (Rybakowski, 2011). Though lithium
is a highly prescribed medicine, its mechanism of action is not
clear. Several lines of studies suggest that clinical efficacy of
lithium is related to its effects on neuroprotection. This is evi-
dent from studies showing increased total gray matter content
(Moore et al., 2000a) and enhanced levels of N-acetyl-aspartate,
a marker of neuronal viability, by lithium in the brain of bipolar
patients (Moore et al., 2000b). Bipolar patients, who are exposed
to lithium, also have greater amygdala gray volume (Chang et al.,
2005). Recently, Gildengers et al. (2014) reported that longer
duration of lithium treatment is associated with higher white
matter integrity. Similarly, the loss of the subgenual prefrontal
cortex volume found in bipolar patients is suppressed in patients
receiving lithium (Drevets, 2001). Given that lithium’s neuropro-
tective action could be associated with clinical improvement, it is
imperative to examine how lithium acts to protect neurons.
The present study aims to delineate such mechanisms. It is
hypothesized that (1) lithium will protect neurons by increas-
ing neuronal viability, dendritic length, and dendritic number, (2)
lithium will increase the expression of BDNF gene and differen-
tially regulate the expression of pro- and anti-apoptotic proteins,
and (3) the effect of lithium on BDNF will be exon specific and
will be epigenetically regulated.
MATERIALS AND METHODS
NEURONAL CULTURE AND LITHIUM TREATMENT
Cryopreserved rat hippocampal neurons were obtained fromUIC
Research Resource Center (Chicago, IL) as a SPOT culture kit
(provided by Dr. Lech Kiedrowaski). Neurons were suspended in
neurobasal medium (Invitrogen, CA). The medium was supple-
mented with 1mM glutamine and 1% B27 (Invitrogen, CA) and
seeded onto culture adhesive coated surfaces provided with the
Spot kit and kept in CO2 chamber at 37◦C. After 3 days, 1mM
glutamine was replaced by 1mM glutamax (Invitrogen, CA) in
the culture medium. Seven days later, lithium chloride (Sigma,
MO) was added to the culture medium to give the final concen-
tration of 1 or 2mM. Another group of neurons was treated with
normal saline (0.9% NaCl2 in phosphate buffer saline). Neuronal
cells were pretreated with lithium or normal saline for 36 h prior
to the addition of glutamate (100μM) for 12 h. Neuronal viabil-
ity and morphology were studied. A separate set of neurons were
treated with lithium (1 or 2mM) for 48 h and the expression of
BDNF as well as pro and anti-apoptotic genes was examined.
NEURONAL VIABILITY
Neuronal viability was assessed using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduc-
tion assay kit (Sigma, MO). MTT (0.5mg/ml) was added to the
culture medium (at a ratio of 1:10) after 48 h of lithium treat-
ment. After 2 h incubation, the medium was taken out; formazon
product was dissolved in dimethylsulfoxide; absorbance was
measured at 570 nm and neuronal viability was calculated. The
results are expressed as a percentage of viability of the control
culture.
IMMUNOFLUORESCENCE STAINING OF CULTURED NEURONS
To determine the effect of lithium on neuronal morphology, neu-
ron cultures were fixed with 4% paraformaldehyde for 30min
at room temperature, permeabilized with 0.25% Triton X-100
in phosphate buffer saline for 10min, blocked with 5% donkey
serum (Jackson Laboratories, PA) for 1 h at room temperature,
and then incubated for 16 h at 4◦C with rabbit anti-microtubule-
associated protein (MAP)2 antibody (Millipore, MA). Dilution
of antibody was 1:1000. This was followed by incubation with
fluorescein labeled donkey anti-rabbit IgG (1:200) (Jackson
Laboratories, PA) for 1 h at room temperature. After washing in
phosphate buffer saline, coverslips were inverted in slides over a
drop of vectashield mounting medium for fluorescence with 4′,6-
Diamidino-2-phenylindole (DAPI) (Vector Labs, CA). Images
were obtained at 40× magnification using the camera attached
to the microscope.
ASSAYS FOR DENDRITIC OUTGROWTH AND NEUROPROTECTIVE
ACTIVITY
Ten photographs per well were obtained from three wells for
each group. Thirty well-stained neurons that made connections
to no more than two cells were selected for measurements of their
primary dendritic length and dendritic number. Dendrites were
defined as processes with a length longer than the cell diameter.
Dendritic length was measured by the software from Neurolucida
(MBF Bioscience, VT), whereas the percentage of cells forming
dendrites was calculated.
DETERMINATION OF mRNA EXPRESSION OF BDNF, BCL2, Bcl-XL, Bad,
Bax, Caspase 3 BY REAL TIME-REVERSE TRANSCRIPTASE
POLYMERASE CHAIN REACTION (RT-PCR)
RNA from hippocampal neurons were isolated using Trizol
kit (Life Technologies, CA). The RNA yield and the ratio of
absorbance at 260 to 280 nm (A260/A280ratio) were measured
with the NanoDrop® Spectrophotometer (Thermo Scientific,
DE). mRNA levels of various genes were determined using a
two-step qPCR (Stratagene Mx3005p). One μg of total RNA was
reverse transcribed using 50 ng random hexamers, 2mM dNTP
mix, 10 u ribonuclease inhibitor, and 200 u MMLV-reverse tran-
scriptase in a final reaction volume of 20μl. The primer/probe
sets were obtained from Applied Biosystems as the TaqMan Gene
Expression Assay kit. The PCR reaction was carried out in a final
volume of 20μl, containing 5μl of cDNA diluted 1:10, 1× of
TaqMan primer/probe mix (20×), and 1× TaqMan® Universal
PCR master mix. For each primer/probe tested, the PCR reac-
tion also included a non-reverse transcription negative control to
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confirm the absence of genomic DNA, a non-template negative
control to check for primer-dimer. The amounts of target genes
expressed in a sample were normalized to GAPDH. Fold changes
between subject groups are measured using the 2−Ct method,
where CT = (CTtarget − CTnormalizer)sample − (CTtarget −
CTendogenousgene)control.
QUANTITATION OF BDNF PROTEIN BY WESTERN BLOT
Gel electrophoresis and immunolabeling of BDNF were per-
formed by Western blot. Primary neuronal culture cells
were homogenized in a Tris buffer containing 5mM EDTA,
1mM phenylmethylsulfonyl fluoride, 5μg/ml each of aprotinin,
leupeptin, pepstatin, and 10μg/ml of 100mM sodium ortho-
vanadate. Equal volumes of samples containing 10μg of pro-
tein were electrophoresed on 10% (w/v) polyacrylamide gel.
The blots were incubated overnight at 4◦C with primary anti-
body for BDNF (1:1000 dilution; RandD Systems, MN) fol-
lowed by horseradish-peroxidase-linked secondary anti-mouse
or anti-rabbit IgG (1:1000 dilution; GE Healthcare Bio-Sciences,
Piscataway, NJ) for 5 h at room temperature. The membranes
were stripped and re-probed with β-actin monoclonal primary
(1:5000 for 1 h, Sigma Chemical Co., St. Louis, MO) and anti-
mouse secondary antibody (1:5000 for 1 h). The bands on the
autoradiograms were quantified using the Loats Image Analysis
System (Westminister, MD). The optical density (O.D.) of each
protein was corrected by the optical density of the corre-
sponding β-actin band. The results are presented as percent of
control.
mRNA EXPRESSION OF BDNF EXONS
RNA was reverse transcribed using the iScript RT-PCR iQ SYBR
Green Supermix (Bio-Rad, Hercules, CA). RT-PCR amplifica-
tions were carried out at 50◦C for 30min; 95◦C for 15min
followed by 40 cycles of 94◦C for 60 s; 57◦C for 60 s; 72◦C for 60 s
and then incubation at 70◦C for 10min, using primers specific
to the rat BDNF exons (I, II, IV, and VI) as described in Table 1.
β-Actin was used as normalizer.
METHYLATION-SPECIFIC RT-PCR FOR BDNF EXON PROMOTER
METHYLATION
DNA was isolated from hippocampal neurons, purified and pro-
cessed for bisulfite modification (Lubin et al., 2008). Methylation-
specific PCR primers are provided in Table 2. β-actin DNA was
evaluated as control. PCR reactions were performed using the fol-
lowing cycling conditions: 95◦C for 3min, 40 cycles of 95◦C for
15 s and 58-60◦C for 1min. Samples were normalized to β-actin
and the comparative Ct method was used to calculate differences
in gene expression between samples.
STATISTICAL ANALYSIS
Each value is expressed as the mean ± standard deviation
(SD). The data were analyzed by SPSS software (Chicago,
IL). Statistical differences between each group were evalu-
ated by One-Way analysis of variance (ANOVA) followed by
Bonferroni correction. Differences were considered significant at
p < 0.05.
RESULTS
NEURONAL DEATH AFTER GLUTAMATE TREATMENT AND ITS
PREVENTION BY LITHIUM
To examine whether lithium is neuroprotective, lithium (1 or
2mM) was added in the culture medium 36 h prior to glutamate
(100μM) addition for 12 h and neuronal viability was assessed.
Glutamate reduced the neuronal viability by 60% (Figure 1). It
was found that this neuronal death was prevented by lithium
in a dose-dependent manner. A dose of 1mM lithium increased
the neuronal viability by 75% whereas 2mM lithium completely
reversed glutamate-induced neuronal death (Figure 1).
Table 1 | Primer sequences for BDNF exons.
BDNF exon I mRNA: CTCAAAGGGAAACGTGTCTCT
TCACGTGCTCAAAAGTGTCAG
BDNF exon II mRNA: CTAGCCACCGGGGTGGTGTAA
TCACGTGCTCAAAAGTGTCAG
BDNF exon IV mRNA: TGCGAGTATTACCTCCGCCAT
TCACGTGCTCAAAAGTGTCAG
BDNF exon VI mRNA: TTGGGGCAGACGAGAAAGCGC
TCACGTGCTCAAAAGTGTCAG
Table 2 | Methyl-specific Real-time PCR Primers.
BDNF exon I Methylated
CGGAAAGTATTAGAGGTAGGGTAGC
TACGAACCCTAAATCTCTAAACGAA
BDNF exon II Methylated
TCGTTGTTAAGTTAATTCGGTGTC
AAACTAAAACTAACTCTCCAAACGCT
BDNF exon IV Methylated
GGTAGAGGAGGTATTATATGATAGTTTACG
TAAATAAAAAAAACGACAACGCGAA
BDNF exon VI Methylated
ATTTTTCGGTTTGGAGAAGGAAATC
TCAAAATCCACACAAAACTCTCGAA
FIGURE 1 | Pretreatment of lithium prevents neuronal death by
glutamate. Lithium (1 or 2mM) was added to the medium 36h prior to
glutamate treatment. Glutamate (100μM) was added 12 h prior to
examining neuronal viability. The data are mean ± SD from 3 independent
experiments. ∗P < 0.001 compared with control group and ∗∗p < 0.001
compared with glutamate treated group.
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EFFECT OF LITHIUM ON DENDRITIC LENGTH AND NUMBER
Morphology of hippocampal neurons was studied in the con-
trol group (no treatment) and after glulatmate (100μM for 12 h)
or glulatamate + lithium (1 or 2mM for 48 h) treatment. The
morphology of neurons was detected using MAP2 antibody, fol-
lowed by treatment with DAPI (Figure 2). It was observed that
the average dendrite length in the control group was 120.51 ±
12.13μm. The average dendritic length in the glutamate group
was 81.45 ± 16.12. When 1mM of lithium was added, the aver-
age dendrite length increased to 100.64 ± 12.11μm. Finally,
when 2mM lithium was added, the dendrite length increased to
117.51 ± 17.10μm (Figure 3).
When dendrite numbers were compared, it was observed that
the average number of dendrites per cell in the control group was
4.0 ± 0.32. Addition of glutamate reduced the dendritic num-
ber to 2.2 ± 0.12. The average number of dendrites per cell in
glutamate +1mM lithium group was 4.4 ± 0.51, whereas in
glutamate +2mM lithium group, it was 4.5 ± 0.62 (Figure 4).
EFFECT OF LITHIUM ON mRNA AND PROTEIN EXPRESSION OF BDNF
Lithium at 1mM concentration increased mRNA expression of
BDNF. The mRNA expression of BDNF was increased by 67%
whereas this effect was further substantiated (100%) at 2mM
lithium (Figure 5A). AWestern blot showing expression of BDNF
is provided in Figure 5B. When quantitatively assessed, the pro-
tein level of BDNFwas significantly increased by both 1 and 2mM
concentrations of lithium (Figure 5C). This increase was 53 and
89% for 1 and 2mM lithium, respectively.
EFFECT OF LITHIUM ON EXPRESSION OF SPECIFIC BDNF PROMOTER
AND METHYLATION OF PROMOTER EXONS
To examine whether BDNF expression induced by lithium is asso-
ciated with specific BDNF promoter(s), mRNA level of various
exons (I, II, IV, and VI) were examined. It was observed that at
1mM, lithium increased exon IV expression by 55% whereas at
2mM, this increase was 98%. There was no significant change in
the expression of exons I, II, and VI by lithium (Figure 6).
DNA METHYLATION OF BDNF GENE PROMOTERS BY LITHIUM
To examine whether the effect of lithium is epigenetically regu-
lated, methylation of exons I, II, IV, and VI was examined. At
FIGURE 3 | Dendritic length after glutamate (100μM) and glutamate +
lithium (1 or 2mM) treatment. Ten photographs per well were obtained
from three wells for each group. Thirty well-stained neurons that made
connections to no more than two cells were selected for measurements of
their primary dendritic length and dendritic number. ∗P < 0.001 compared
with control group and ∗∗p < 0.001 compared with glutamate treated
group.
FIGURE 2 | Neuronal morphology after glutamate (100μM) and glutamate + lithium (1 or 2mM) treatment. Treatment of glutamate and lithium was the
same as mentioned in Figure 1.
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the dose of 1mM, lithium decreased methylation of exon IV
by 38%, whereas at the dose of 2mM, this decrease was 50%.
Methylation of promoters I, II, and VI was not affected by lithium
(Figure 7).
EFFECT OF LITHIUM ON EXPRESSION OF PRO- AND ANTI-APOPTOTIC
GENES
As can be seen in Figure 8A, lithium increased the expression of
Bcl2 (1mM of lithium: 1.57 ± 0.15 fold; 2mM lithium: 1.83 ±
0.12 fold) and Bcl-XL (1mM of lithium: 1.17 ± 0.06 fold; 2mM:
1.43 ± 0.12 fold) in a dose dependent manner. Lithium did
FIGURE 4 | Dendritic number after glutamate (100μM) and
glutamate + lithium (1 or 2mM) treatment. The data are mean ± SD
from 3 independent experiments. ∗P < 0.001 compared with control group
and ∗∗p < 0.001 compared with glutamate treated group.
not show any change in the expression of Bax at 1mM dose
but decreased its expression (0.80 ± 0.10 fold) (Figure 8B). The
expression of BAD was decreased by both doses of lithium,
the magnitude of change being higher at 2mM (1mM lithium:
0.60 ± 0.00 fold; 2mM of lithium: 0.27 ± 0.06 fold) (Figure 8B).
Finally, caspase 3 expression was also decreased by both doses
of lithium, higher dose being more effective that the lower dose
(1mM lithium: 0.57 ± 0.06 fold; 2mM lithium: 0.33 ± 0.06 fold)
(Figure 8B).
DISCUSSION
In the present study, we used two different doses of lithium:
1mM, which is in the clinical range, and 2mM, which is
slightly higher than the clinical range (reviewed in Young, 2009).
Although higher dose has clinical side effects, we wanted to
FIGURE 6 | Effect of lithium (1 or 2mM) on expression of individual
BDNF exons after 48h after lithium (1 or 2mM) treatment. The data are
mean ± SD from 3 independent experiments. ∗P < 0.001 compared with
control group.
FIGURE 5 | (A) BDNF mRNA expression after 48 h of lithium (1 or
2 mM) treatment. ∗P < 0.001 compared with control group. (B)
Western blots showing immunolabeling of BDNF and β-actin in
hippocampal neurons after 1 or 2 mM lithium treatment. (C) Bar
diagram showing effect of lithium on protein expression of BDNF.
The results are presented as percent of control. The data are
mean ± SD from 3 independent experiments. ∗P < 0.001 compared
with saline treated group.
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FIGURE 7 | DNA methylation of BDNF exons after 48h of lithium (1 or
2mM) treatment. The data are mean ± SD from 3 independent
experiments. ∗P < 0.001 compared with control group.
FIGURE 8 | Effects of 48h of lithium (1 or 2mM) on the expression of
anti-apoptotic (A) and pro-apoptotic (B) genes. The data are mean ± SD
from 3 independent experiments. ∗P < 0.001 compared with control group.
examine whether the side effects are associated with lithium
neurotoxicity. Interestingly, this higher dose (2mM) has been
shown to be neuroprotective against amelospheroid-induced tox-
icity in rat forebrain cholinergic neurons (Hoshi et al., 2003). The
neuroprotective action of lithium was tested against glutamate-
induced neurotoxicity (Hassel and Dingledine, 2006), which has
been shown to be increased in CSF, plasma, and serum (Hoekstra
et al., 2006) as well as in brain (Hashimoto et al., 2007) of bipolar
patients. Abnormalities in the expression of glutamate receptors
(McCullumsmith et al., 2007; Fountoulakis, 2012) and polymor-
phisms in genes coding for glutamate receptors (Itokawa et al.,
2003; Fiorentino et al., 2014; Kandaswamy et al., 2014) have also
been reported in bipolar patients. It was found that both doses
of lithium were effective in preventing neuronal cell death; higher
dose was slightly more effective than the lower dose. From our
study, it appears that the higher dose of lithium is neuroprotective
and its clinical side effects may be associated with actions other
than protecting neurons.
When dendritic morphology was studied, it was found that
both doses of lithium increased dendritic length and number. As
has been reported, stress plays a major role in mood disorders
(Watson et al., 2004) and impaired stress response is associ-
ated with hyperglutamatergic state in BD (Zarate et al., 2006).
Both stress and hyperglutamatergic state can lead to alterations
in spine density and number (Sapolsky, 2000). From our data, it
appears that by restoring glutamate-induced changes in neuronal
morphology, lithium exerts its neuroprotective action.
BDNF, a molecule implicated in neuronal survival and synap-
tic plasticity, has been shown to be less expressed in the brain of
bipolar patients (Kapczinski et al., 2008). Also, in hippocampus
and amygdala of rats showing manic behavior, the expression of
BDNF is decreased (Jornada et al., 2010). Under both conditions,
lithium normalizes the decreased level of BDNF (Jornada et al.,
2010; Wu et al., 2014). As with these studies, the present study
also demonstrates that lithium is highly effective in increasing the
level of BDNF in hippocampal neurons. To further examine the
mechanism of lithium-induced higher expression of BDNF, var-
ious BDNF transcripts were examined. The BDNF gene in rats
consists of nine exons; out of which each exon I, II, IV and VI
encodes a 5′-UTR of the BDNF transcript (Aid et al., 2007).When
examined, it was found that both 1 and 2mM doses of lithium
increased the expression of selective exon IV. On the other hand,
the expression of other exons (I, II, and VI) were not affected.
The present study thus suggests that exon IV-containing BDNF
transcripts are responsible for total BDNF expression by lithium.
Gene expression in the nervous system can be modulated by
various mechanisms. One of the most prominent mechanisms
is through epigenetic modifications. In the present study, it was
examined whether increased expression of BDNF gene by lithium
was modulated via DNA methylation of BDNF exons. Using
methylation-specific primers, it was observed that lithium signif-
icantly decreased the methylation of the same specific promoter,
i.e., promoter IV, which was found to be elevated in hippocampal
neurons treated with lithium. The methylation of other promot-
ers such as I, II, and IV was not altered. These results demon-
strate that increased expression of BDNF gene is associated with
hypomethylation mediated by lithium. Recently, D’Addario et al.
(2012) reported that BDNF expression is downregulated in bipo-
lar patients, which was associated with hypermethylation of the
BDNF promoter region. These investigators did not study which
specific promoter region of BDNF was altered; nevertheless, from
the present study, it appears that lithium’s clinical efficacy could
be associated with alteration in the methylation of the exon IV
BDNF transcript.
The present study also shows that lithium dose dependently
increased the expression of antiapoptotic genes Bcl2 and BclXL.
On the other hand, lithium decreased expression of pro-apoptotic
genes Bad, Bax, and caspase 3. Both the doses were effective in
lowering Bad and caspase 3; however, the lower dose was ineffec-
tive on Bax. Thus, neuroprotective mechanisms of lithium could
also be attributed to its action on apoptotic regulatory genes.
Interestingly, a recent study shows that bipolar patients who
respond to lithium show increased ratio of anti- to pro-apoptotic
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genes in blood cells, whereas patients who do not respond to
lithium had no significant effect (Lowthert et al., 2012). Thus, it
is quite possible that effects on pro- and anti-apoptotic genes may
be a prerequisite for lithium action in clinical response to BD.
The mechanism by which lithium modulates the transcrip-
tion of pro- and anti-apoptotic genes is not clear; however, there
may be several possibilities. One could be that BDNF-induced
activation of ERK signaling may lead to increased expression of
these genes. For example, BCL2 gene contains binding sites for
cyclicAMP response element binding protein, a transcription fac-
tor that is activated by ERK1/2. Interestingly, lithium has earlier
been shown to upregulate ERK expression in cultured cells and in
frontal cortex and hippocampus of rat (Chen and Manji, 2006).
Lithium also upregulates the expression of BAG-1, a gene that
binds to and increases the activity of BCL2 (Zhou et al., 2005).
Thus, the effect of lithium on BCL2 could be associated with
increased expression of BAG-1. The other possibility could be of
increased RNA polymerase activity and thereby increased gene
expression by lithium. Further studies will be needed to examine
such mechanisms.
Overall, this study provides several mechanisms by which
lithium may exert its neuroprotective action. Most prominently,
its action on DNA methylation of promoter IV of BDNF and
on apoptotic regulatory proteins appears to be directly related
to its neuroprotective action. Another point to be noted is
that although done in in-vitro, nevertheless, our study clearly
shows that even higher dose was effective in protecting neu-
rons. Paradoxically, the higher doses >2mM have been shown
to have several side effects; however, they do not appear to be
associated with neurotoxicity as 2mM was effective in reversing
glutamate-induced neural viability and protecting neurons. These
studies must take into account the limitations presented by an in-
vitro study and needs to be validated in in-vivo to fully evaluate
lithium’s neuroprotective activity in the human population.
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